MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI

Recruiting now · Phase 2

Conditions studied: Mesothelioma

In brief

In this research study, investigators will test whether prophylactic high-dose IV Mg administration attenuates the risk of AKI in patients with malignant mesothelioma receiving intraoperative chemotherapy (HIOC) with cisplatin compared to placebo .

Key facts

Study ID

NCT05730816

Run by

Brigham and Women's Hospital

People needed

130

Starts

2023-04-04

Expected to finish

2028-01-01

Last updated by the study team

2025-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• • Adult patients (≥18 years old) with malignant mesothelioma undergoing surgery with HIOC with Dr. Raphael Bueno or another BWH thoracic surgeon

You may not qualify if…

• eGFR<45 ml/min/1.73m2 on either screening labs or preoperative labs, or end-stage kidney disease receiving renal replacement therapy. Screening labs refer to those obtained at the preoperative visit with the surgeon or within 90 days prior, whereas preoperative labs are obtained on the day of admission (typically one to three days priors to surgery).
• Serum Mg >3 mg/dl on either screening labs or preoperative labs
• Pregnant/breastfeeding
• Neuromuscular disease (e.g., myasthenia gravis, amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myositis)
• Coronary artery disease, defined as any of the following in the prior year: a positive stress test; coronary angiogram indicating 1 or more vessels with >70% stenosis; percutaneous coronary intervention with stents; or coronary artery bypass graft surgery
• Sinus bradycardia, defined as a heart rate (HR) <55 beats per minute (bpm) detected on any ECG in the preceding 6 months
• High grade AV block (2nd degree AV block type II or 3rd degree AV block) without a pacemaker
• Positive COVID test in the 10 days prior to surgery
• Prisoner
• Hypersensitivity to Mg sulfate
• Concurrent participation in a study with an alternative experimental therapy that may interact with IV Mg
• Any condition that, in the view of the PI, might place the patient at increased risk or compromise the integrity of the study
• Conflict with other study

Where it is running

• Brigham and Women's Hospital — Boston, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.